Navigation Links
ev3 Inc. Appoints John L. Miclot to Board of Directors
Date:12/3/2008

PLYMOUTH, Minn., Dec. 3 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today announced the appointment of John L. Miclot to its Board of Directors effective immediately.

Mr. Miclot is currently the president and chief executive officer of CCS Medical, a privately held nationwide provider of various home care products for chronic diseases such as diabetes, wound care, urology and respiratory disorders. Prior to joining CCS Medical, Mr. Miclot served as chief executive officer of Philips Home Healthcare Solutions from March 2008 until November 2008 following the acquisition of Respironics, Inc. by Philips. From December 2003 to March 2008, Miclot served as president and chief executive officer of Respironics, Inc. Prior to that, Mr. Miclot served in various positions at Respironics, Inc. from 1998 to 2003, including chief strategic officer and president of the Homecare Division. Mr. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies where he had served as senior vice president, sales and marketing from 1995 to 1998.

Mr. Miclot currently serves on the board of directors of Wright Medical Group and several private companies including CCS Medical.

"We are delighted to have someone with John's proven leadership skills and extensive operational expertise join our board," said Robert Palmisano, president and chief executive officer of ev3. "John's insight and experience will be of great value as we work towards building the premier endovascular company and preferred physician partner for identifying and treating peripheral vascular and neurovascular disease."

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.

ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.


'/>"/>
SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
2. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. InCode BioPharmaceutics Appoints New President and CEO
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. GeneNews appoints Canadian Colorectal Cancer Advisory Board
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. Accumetrics Appoints John J. Young, MD Chief Medical Officer
11. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer — a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... , Dec. 7, 2016  Nordion, a ... General Atomics (GA), welcome today,s award by the ... Security Administration (NNSA) of the Phase II cooperative ... with Nordion and the University of Missouri Research ... funding will support the establishment of a new, ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced today ... the company,s Board of Directors. "We are ... build our business and develop our oncolytic viruses as ... said Stephen Russell , MD, PhD, CEO of ... share our vision and passion for making a difference ...
(Date:12/7/2016)... YORK and ANN ARBOR, Mich. ... privately held biopharmaceutical company developing breakthrough immune modulatory medicines, ... trial of the Company,s lead therapeutic candidate, LYC-30937- E ... is often a debilitating skin disease that is estimated ... the United States , with approximately 1.5 ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):